Expert insights. Personalized for you.
Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. Cabot Wealth Management Inc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $4.15B market cap company. MORE
Here’s a quick blurb……… The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of … Read More. MORE
Canopy Growth Corporation acquired a patented cannabis extraction technique that GW Pharmaceuticals allegedly infringed. Greenwich Biosciences is a US subsidiary of GW Pharmaceuticals […]. MORE
The post MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics first appeared on Cannabis Law Report. MORE
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. ICC International Cannabis Corp. CSE: WRLD.U)(FWB: MORE
More Women Switch Out Pharmaceuticals For Medical Marijuana. The post More Women Switch Out Pharmaceuticals For Medical Marijuana appeared first on The Fresh Toast. Medical Marijuana News Endometriosis gynecology menopause pharmaceuticals prescription drugs women MORE
TSXV: LG and OTC-QB: LGGCF) (“ LGC ”) is pleased to announce that it has paid the 2 nd Tranche, as contractually agreed, in acquiring an equity interest in the Italian pharmaceutical company, Freia Farmaceutici Srl (“Freia”). It should be noted that Freia’s products are currently authorized under the framework of pharmaceutical law and not subject to the evolving, provisional regulation of cannabis. This EU pharmaceutical entity is an optimal addition to LGC. MORE
Clever Leaves expands global capabilities and development of market specific pharmaceutical products. The post Clever Leaves Successfully Delivers First Shipment of EU GMP certified Cannabis derived Pharmaceuticals from Colombia to Germany first appeared on Cannabis Law Report. MORE
CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. Here’s the press release. MORE
Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Dr. Sophon Mektana, Advisor to the Minister of Public Health And the Chairman of the Pharmaceutical Organization Committee. MORE
Cann Group COO: ‘we need to put our “big boy pants on” and adopt a pharmaceutical mindset’ first appeared on Cannabis Law Report. Actually there’s two things in that headline that illustrate why Australia has a long way to go That it is… Read More. MORE
According to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to distribute its GMP products to pharma customers, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel. Forbes report. MORE
GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More. Breaking News MORE
Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. Some of the players covered in the study are Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics, Axim Biotechnologies, Medical Marijuana, Zynerba, Pain Management Device Players:, Boston Scientific Crop., MORE
3, 2020 /PRNewswire/ — Pure Jamaican Limited , provider of pharmaceutical cannabinoids, genetics and consumer packaged goods products in large volumes for … Read More. MIAMI , Dec. MORE
The post Jazz Pharmaceuticals Pick Up GW Pharma For A Cool $7.2 For those of you living under a rock here is the news. We thought we better report it along with… Read More. billion first appeared on Cannabis Law Report. Breaking News MORE
1) We were curious if there is any weight to Canopy’s new infringement allegations against GW Pharmaceuticals (GWPH). A patent for CO2 extraction of cannabis has been acquired by Canopy Growth Corporation (TSX:WEED), but will small cannabis companies become potential targets? (1) MORE
Consumers Are Replacing Pharmaceuticals With Medical Marijuana In recent years, certain states that have medical and/or recreational cannabis programs in place have experienced decreases in the number of opioid overdoses. The post Consumers Are Replacing Pharmaceuticals With Medical Marijuana appeared first on The Fresh Toast. Cannabis Medical Marijuana News opioids pharmaceuticals MORE
Health Politics cannabidiol cbd Epidiolex GW Pharma GW PharmaceuticalsPrescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. MORE
8, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced […]. The post Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks. MORE
The post European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs first appeared on Cannabis Law Report. Download as PDF October 05, 2020 A milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large … Read More. Press Release EU ZA MORE
The mycology-focused company has signed an agreement with Applied Pharmaceutical Innovation (API), … Read More. Mydecine ( MYCO.CN ) ( NLBIF ) is quickly upping its fungi authority. Psy Business & Law News Partnered With CFN MORE
study shows that more and more people are giving up alcohol and pharmaceuticals in favour of cannabis use. are moving away from alcohol and pharmaceuticals in favour of cannabis use. Taking cannabis user archetypes beyond the traditional medical/recreational binary, the study developed nine distinct cannabis consumer profiles and looked at their use of alcohol, pharmaceuticals and cannabis to gain greater insight into the full spectrum of consumer values, lifestyles and behaviours. MORE
The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states. Greenwich Biosciences , the United States subsidiary of the British GW Pharmaceuticals , registered to lobby in every single state in the country—including ones where all forms of cannabis are prohibited—over the last three years. The Incredibly Large Lobbying Footprint of Greenwich Biosciences. MORE
The post February 4 2021: Jazz Pharmaceuticals buys GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV MORE
This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol. on the new pharmaceutical, and that the vast majority of these side effects are not from any extract of Cannabis, including CBD. Why would a pharmaceutical company do this? MORE
12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. Enquiries: GW Pharmaceuticals plc. MORE
The post February 4 2021: Jim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV MORE
Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. It is important that the pharmaceutical industry continues to work with the medical advisory body to ensure that drugs are cost effective and that its long-term effects are clear.” About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. MORE
CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. About Zhejiang Yatai Pharmaceutical Co., MORE
SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV). MORE
There have been calls to loosen regulations around medical cannabis to increase access for those who need it, but the government must resist and view cannabis with the same scrutiny as any other new medicine. Read all at ( paywall) [link]. Medical Cannabis News MORE
Jazz Pharmaceuticals finalized a deal with GW Pharmaceuticals, one of the first and largest producers of legal cannabis-based medicines. GW Pharma ($GWPH) stock jumped nearly 50% after they agreed to sell to Jazz for a landslide of $7.2 billion. MORE
There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine). MORE
SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV). MORE
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. MORE
Here’s their press release: … Read More. Mark Taylor UK / EU Cannabis Compliance Blog MORE
To create, develop and market a variety of high content cannabinoid based pharmaceuticals, natural health products and cosmetics for international markets. CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a non-binding letter of intent of strategic cooperation with China-based Zhejiang Yatai Pharmaceutical Co., MORE
Pharmaceutical Related Topics The Fresh Toast
NOVEMBER 21, 2020
More Women Switch Out Pharmaceuticals For Medical Marijuana. The post More Women Switch Out Pharmaceuticals For Medical Marijuana appeared first on The Fresh Toast. Medical Marijuana News Endometriosis gynecology menopause pharmaceuticals prescription drugs women
The Fresh Toast
MARCH 20, 2019
Consumers Are Replacing Pharmaceuticals With Medical Marijuana In recent years, certain states that have medical and/or recreational cannabis programs in place have experienced decreases in the number of opioid overdoses. The post Consumers Are Replacing Pharmaceuticals With Medical Marijuana appeared first on The Fresh Toast. Cannabis Medical Marijuana News opioids pharmaceuticals
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 20, 2020
Here’s a quick blurb……… The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of … Read More.
Cannabis Law Report
FEBRUARY 3, 2021
The post February 4 2021: Jazz Pharmaceuticals buys GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV
Cannabis Law Report
FEBRUARY 3, 2021
The post February 4 2021: Jim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV
Cannabis Law Report
NOVEMBER 23, 2020
The post MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics first appeared on Cannabis Law Report.
|
Cannabis Law Report
SEPTEMBER 24, 2019
Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. It is important that the pharmaceutical industry continues to work with the medical advisory body to ensure that drugs are cost effective and that its long-term effects are clear.” About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Cannabis Law Report
DECEMBER 12, 2020
Clever Leaves expands global capabilities and development of market specific pharmaceutical products. The post Clever Leaves Successfully Delivers First Shipment of EU GMP certified Cannabis derived Pharmaceuticals from Colombia to Germany first appeared on Cannabis Law Report.
Cannabis Law Report
MAY 12, 2020
GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More. Breaking News
Cannabis Life Network
FEBRUARY 11, 2021
1) We were curious if there is any weight to Canopy’s new infringement allegations against GW Pharmaceuticals (GWPH). A patent for CO2 extraction of cannabis has been acquired by Canopy Growth Corporation (TSX:WEED), but will small cannabis companies become potential targets? (1)
Cannabis Law Report
DECEMBER 3, 2020
3, 2020 /PRNewswire/ — Pure Jamaican Limited , provider of pharmaceutical cannabinoids, genetics and consumer packaged goods products in large volumes for … Read More. MIAMI , Dec.
|
|
Cannabis Law Report
JUNE 28, 2020
The mycology-focused company has signed an agreement with Applied Pharmaceutical Innovation (API), … Read More. Mydecine ( MYCO.CN ) ( NLBIF ) is quickly upping its fungi authority. Psy Business & Law News Partnered With CFN
Cannabis Law Report
NOVEMBER 10, 2019
Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. Some of the players covered in the study are Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics, Axim Biotechnologies, Medical Marijuana, Zynerba, Pain Management Device Players:, Boston Scientific Crop.,
Cannabis Law Report
OCTOBER 7, 2020
The post European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs first appeared on Cannabis Law Report. Download as PDF October 05, 2020 A milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large … Read More. Press Release EU ZA
Cannabis Law Report
FEBRUARY 24, 2021
Cann Group COO: ‘we need to put our “big boy pants on” and adopt a pharmaceutical mindset’ first appeared on Cannabis Law Report. Actually there’s two things in that headline that illustrate why Australia has a long way to go That it is… Read More.
Cannabis Life Network
OCTOBER 8, 2019
8, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced […]. The post Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.
Leaf Science
DECEMBER 28, 2018
study shows that more and more people are giving up alcohol and pharmaceuticals in favour of cannabis use. are moving away from alcohol and pharmaceuticals in favour of cannabis use. Taking cannabis user archetypes beyond the traditional medical/recreational binary, the study developed nine distinct cannabis consumer profiles and looked at their use of alcohol, pharmaceuticals and cannabis to gain greater insight into the full spectrum of consumer values, lifestyles and behaviours.
Canna Newswire
MAY 21, 2019
To create, develop and market a variety of high content cannabinoid based pharmaceuticals, natural health products and cosmetics for international markets. CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a non-binding letter of intent of strategic cooperation with China-based Zhejiang Yatai Pharmaceutical Co.,
Cannabis Law Report
JULY 23, 2019
TSXV: LG and OTC-QB: LGGCF) (“ LGC ”) is pleased to announce that it has paid the 2 nd Tranche, as contractually agreed, in acquiring an equity interest in the Italian pharmaceutical company, Freia Farmaceutici Srl (“Freia”). It should be noted that Freia’s products are currently authorized under the framework of pharmaceutical law and not subject to the evolving, provisional regulation of cannabis. This EU pharmaceutical entity is an optimal addition to LGC.
Canna Newswire
MAY 30, 2019
CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. About Zhejiang Yatai Pharmaceutical Co.,
Puff Puff Post
MARCH 10, 2020
SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Cannabis Law Report
JULY 12, 2019
This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol. on the new pharmaceutical, and that the vast majority of these side effects are not from any extract of Cannabis, including CBD. Why would a pharmaceutical company do this?
Cannabis Law Report
JULY 21, 2019
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. ICC International Cannabis Corp. CSE: WRLD.U)(FWB:
Cannabis Law Report
JULY 19, 2019
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry.
Cannabis Life Network
FEBRUARY 5, 2021
Jazz Pharmaceuticals finalized a deal with GW Pharmaceuticals, one of the first and largest producers of legal cannabis-based medicines. GW Pharma ($GWPH) stock jumped nearly 50% after they agreed to sell to Jazz for a landslide of $7.2 billion.
Cannabis Life Network
JANUARY 5, 2021
Canopy Growth Corporation acquired a patented cannabis extraction technique that GW Pharmaceuticals allegedly infringed. Greenwich Biosciences is a US subsidiary of GW Pharmaceuticals […].
Cannabis Law Report
JANUARY 13, 2020
12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. Enquiries: GW Pharmaceuticals plc.
Cannabis Law Report
OCTOBER 26, 2019
The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states. Greenwich Biosciences , the United States subsidiary of the British GW Pharmaceuticals , registered to lobby in every single state in the country—including ones where all forms of cannabis are prohibited—over the last three years. The Incredibly Large Lobbying Footprint of Greenwich Biosciences.
Cannabis Life Network
AUGUST 22, 2020
There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine).
Cannabis Law Report
SEPTEMBER 14, 2019
According to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to distribute its GMP products to pharma customers, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel. Forbes report.
Puff Puff Post
MARCH 10, 2020
SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Cannabis Law Report
MAY 30, 2019
CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. Here’s the press release.
Cannabis Law Report
JUNE 24, 2020
Here’s their press release: … Read More. Mark Taylor UK / EU Cannabis Compliance Blog
Cannabis Law Report
NOVEMBER 5, 2019
Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. Cabot Wealth Management Inc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $4.15B market cap company.
Cannabis Law Report
JULY 13, 2019
There have been calls to loosen regulations around medical cannabis to increase access for those who need it, but the government must resist and view cannabis with the same scrutiny as any other new medicine. Read all at ( paywall) [link]. Medical Cannabis News
Leafly
APRIL 6, 2020
Health Politics cannabidiol cbd Epidiolex GW Pharma GW PharmaceuticalsPrescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly.
Cannabis Law Report
JUNE 5, 2019
Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Dr. Sophon Mektana, Advisor to the Minister of Public Health And the Chairman of the Pharmaceutical Organization Committee.
43 
Let's personalize your content